Table 3.
Results of Multiple Logistic Regression to Determine Predictors of Drug Shortage Risk
| Variable | Odds Ratio (95% CI)a |
|---|---|
| Dosage form | |
| Oral only | 0.20 (0.11-0.35) |
| Oral and IV | 2.41 (1.43-4.13) |
| IV only | 3.94 (1.43-4.13) |
| Therapeutic class | |
| Antipsychotic | 0.24 (0.06-0.79) |
| Antineoplasticb | 0.71 (0.36-1.36) |
| Cardiovascular | 1.90 (1.15-3.15) |
| Antimicrobial | 3.68 (2.28-5.98) |
| Analgesic | 8.41 (4.00-18.1) |
| Anesthetic | 12.9 (3.17-65.3) |
| Electrolyte | 101.1 (30.1-481.7) |
| Controlled substance schedule | |
| Schedule II | 0.19 (0.07-0.51) |
| Schedules III–Vb | 2.47 (0.96-7.05) |
| Orphan drug status | 0.45 (0.25-0.77) |
| Branded/generic product availability | |
| Branded only | 0.03 (0.02-0.06) |
| Generic onlyb | 1.12 (0.76-1.64) |
| No. of manufacturers | 0.11 (0.08-0.17) |
Abbreviations: CI, confidence interval; IV, intravenous.
aMultiple logistic regression intercept, 0.44 (0.14-1.23).
b P > 0.05 for association with drug shortage risk.